Übersetzung für "Neoplastic disease" in Deutsch

The compounds according to the invention can be used for the treatment of neoplastic disease.

In view of the situation described, it would be extremely desirable to have a method which provides reliable information about the presence of any tumour disease (i.e. malignant neoplasms) with a very high sensitivity, so that, optionally by additionally taking into account the clinical picture of the patient investigated in order to avoid misinterpretations of the measured results, optionally further diagnostic measures for more exact localization and differential diagnosis of the neoplastic disease detected are then justified.

Physical activity, which stimulates the immune system of the organism and modifies its hormonal and metabolic function, is a significant factor in primary and secondary prevention of the neoplastic disease.

The Centre includes Rehabilitation Department for women after a neoplastic disease of female reproductive organs, and the Sanatorium Department for other patients following oncological treatment.

The method according to any claim from 2 to 9, wherein the malignant neoplastic disease is selected from the group consisting of breast, urothelial, colorectal, esophageal, gastric, hepatocellular carcinoma, lung, melanoma, nasopharyngeal, multiple myeloma, renal cell carcinoma, lymphomas, oropharyngeal squamous cell carcinoma, cervical, glioblastoma, malignant mesotheliomas, ovarian and pancreatic cancer.

Humanized antibody or a fragment thereof according to claim 12, for use in the treatment of neoplastic disease, selected from pancreatic tumour or bladder tumour, more preferably pancreatic tumour.

Humanized antibody or a fragment thereof for use according to claim 11, in the treatment of neoplastic disease, selected from pancreatic tumour or bladder tumour, more preferably pancreatic tumour.

Sialadenosis is a non-inflammatory, non-neoplastic parenchymatous disease affecting, above all, the parotid gland.

Many patients use this drug to treat different types of pain, such as headaches, toothaches, athralgia, neuralgia, myositis, visceral pain or pain caused by neoplastic disease.

The marker substance determined according to the invention is a humoral marker substance which indicates with very high sensitivity (correct detection of samples of persons suffering from the disease) the presence of neoplasms in patients and additionally a particular risk situation/prognosis for patients in whom such neoplasms are not yet clinically manifest but who, because of, for example, their circumstances of life (for example exposure during work; smoking) and/or a previous disease and/or medical treatment, are exposed to a particular statistical risk of developing a malignant neoplastic disease.

Etoposide is used for the treatment of various neoplastic diseases.

There may also be a contribution to the causation of neoplastic diseases by a pathologically increased activity of leukocytes.

Hence the immunosuppressive therapy according to the invention is likewise advisable for these neoplastic diseases.

Fecal Calprotectin is a marker for inflammatory and neoplastic gastrointestinal diseases.

Larissa, They organized for the fourth year walking against the disillusionment of neoplastic diseases.

Larissa, organized for the fourth year walking against the disillusionment of neoplastic diseases.

The splice variants of the invention can be used according to the invention as targets for diagnosis and therapy of neoplastic diseases.

In order to address this very serious problem, which may be a danger to public health, detailed government studies are required into neoplastic degenerative brain diseases, the effects of electromagnetic radiation as a whole on the homeostasis of the human organism and so forth.

The Commission's ambitious target of reducing the burden of neoplastic diseases by 15% between now and 2020 can be considered realistic only if this methodology is applied and bolstered by adequate funding.

Concomitant joint problems like early osteoarthritis, subchondral bone defects, instability of the joint, lesions of ligaments or of the meniscus, abnormal weight distribution in the joint, varus or valgus malalignment, patellar malalignment or instability, and metabolic, inflammatory, immunological or neoplastic diseases of the affected joint are potential complicating factors.

Examples of pathological states in which an immunosuppressant of this type can be used are those with a chronic inflammatory process such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis and other autoimmune diseases, degenerative disorders such as Parkinson's disease, arteriosclerosis, neoplastic diseases, hyperergic/allergic disorders, graft-versus-host reactions, shock syndrome such as ARDS (adult respiratory distress syndrome), post-burn disorder, consumption Coagulopathy and sepsis.

An effective amount of transglutaminases for inhibiting the damage in tissue at risk during reperfusion, in inflammatory processes, subarachnoid hemorrhages, autoimmune diseases, degenerative disorders, arteriosclerosis, neoplastic diseases (such as leukemias, histiocytosis X and others), hyperergic/allergic disorders, post-burn disorder, transplant incompatibility, premature detachment of the placenta and pre-eclampsia, shock syndrome, depends on a number of factors, for example the age and the weight of the patient and the clinical condition.

In comparison with the strong tumour-inhibiting activity, the toxicity and side-effects of the compounds according to the invention are low to moderate (maximum single dose tolerated: intraperitoneal administration: between 500 and 1250 mg/kg; and oral administration: more than 2500 mg/kg), so that they can be used as such or, especially, in the form of pharmaceutical preparations for the treatment of neoplastic diseases in warm-blooded animals by enteral, especially oral, or parenteral administration of therapeutically effective doses, and especially for the treatment of mammary carcinoma.

For example, on the basis of the administration protocols known from the literature for the natural products used in the chemotherapy of neoplastic diseases (see Goodman and Gilman's, The Pharmacological Basis of Therapeutics, Macmillan Publishing Company, New York, 7th Edition, pages 1240-1247 and 1277-1289 (1985)) the first administration of a pyrimido[5,4-d]pyrimidine of formula I or a physiologically acceptable acid addition salt thereof conveniently takes place before or together with administration of the chemotherapeutic agent used or before or together with administration of a combination of several chemotherapeutic agents (see DeVita et al. in "Cancer, Principles & Practice of Oncology", 2nd Edition, J. B. Lippincott Company Philadelphia).

The present invention is also concerned with the use of compounds of general formula (II), wherein R can also be a hydrogen atom, for combatting neoplastic diseases.

The present invention is concerned with new N-(2'-aminophenyl)-benzamide derivatives, a process for the preparation thereof, pharmaceutical compositions containing them, and the use thereof for combatting neoplastic diseases.

Neoplastic diseases that may be considered for treatment with the aid of the fusion polypeptides according to the invention or pharmaceutical compositions containing these fusion polypeptides include for example bronchial carcinomas and other tumors of the thorax and mediastinum, breast cancers and other gynecological tumors, colorectal carcinomas, pancreatic carcinomas and other tumors of the gastrointestinal tract, malignant melanomas and other skin tumors, tumors in the head and neck region, prostate carcinomas and other urogenital tumors, sarcomas, endocrine-active tumors, leukemias and Myelodysplastic Syndromes and Hodgkin lymphomas and non-Hodgkin lymphomas.